Migration of Skin Dendritic Cells in Response to Ionizing Radiation Exposure

Department of Microbiology, University of Rochester Medical Center, Rochester, New York 14642, USA.
Radiation Research (Impact Factor: 2.91). 07/2009; 171(6):687-97. DOI: 10.1667/RR1600.1
Source: PubMed


We describe an imaging assay that monitors the migration of two unique subsets of immune dendritic cells (DC), interstitial dendritic cells (iDC) and Langerhans cells (LC), found in the dermal and epidermal layers of skin, respectively. Using this assay, we study responses of these cells to ionizing radiation. Results obtained using whole-mount histology and fluorescence microscopy suggest that ionizing radiation triggered the migration of both major histocompatibility complex (MHC) class II(+) iDC and Langerin(+) LC in a dose- and time-dependent manner. Migration appeared to be limited by local administration of recombinant IL-12, a potent immunostimulatory cytokine known to induce DNA repair. Those findings were extended to an in vivo model by injecting fluorescently conjugated anti-MHC class II antibodies intradermally into the ears of live, anesthetized mice and visualizing the DC population in the same ear before and after radiation exposure using confocal microscopy.

1 Follower
14 Reads
  • Source
    • "While the mechanism of increased DC migration to skin-draining lymph nodes after ionizing radiation remains unclear, acute radiation toxicity of the skin is associated with elevated levels of inflammatory cytokines and chemokines, including IL-1α, IL-1β, TNF-α, CCL4, CXCL10, and CCL2 [30-32]. Of the major groups of skin-derived DCs, both the epidermal LCs and the dermal DCs have been found to be depleted from the skin following local irradiation [33]. Our data identifying an increase in skin-derived DCs in the inguinal lymph nodes 24 hours following irradiation suggests that these skin DCs have indeed migrated to the draining lymph nodes, rather than dying off within the skin. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The development of successful cancer vaccines is contingent on the ability to induce effective and persistent anti-tumor immunity against self-antigens that do not typically elicit immune responses. In this study, we examine the effects of a non-myeloablative dose of total body irradiation on the ability of tumor-naïve mice to respond to DNA vaccines against melanoma. We demonstrate that irradiation followed by lymphocyte infusion results in a dramatic increase in responsiveness to tumor vaccination, with augmentation of T cell responses to tumor antigens and tumor eradication. In irradiated mice, infused CD8(+) T cells expand in an environment that is relatively depleted in regulatory T cells, and this correlates with improved CD8(+) T cell functionality. We also observe an increase in the frequency of dendritic cells displaying an activated phenotype within lymphoid organs in the first 24 hours after irradiation. Intriguingly, both the relative decrease in regulatory T cells and increase in activated dendritic cells correspond with a brief window of augmented responsiveness to immunization. After this 24 hour window, the numbers of dendritic cells decline, as does the ability of mice to respond to immunizations. When immunizations are initiated within the period of augmented dendritic cell activation, mice develop anti-tumor responses that show increased durability as well as magnitude, and this approach leads to improved survival in experiments with mice bearing established tumors as well as in a spontaneous melanoma model. We conclude that irradiation can produce potent immune adjuvant effects independent of its ability to induce tumor ablation, and that the timing of immunization and lymphocyte infusion in the irradiated host are crucial for generating optimal anti-tumor immunity. Clinical strategies using these approaches must therefore optimize such parameters, as the correct timing of infusion and vaccination may mean the difference between an ineffective treatment and successful tumor eradication.
    PLoS ONE 12/2013; 8(12):e82496. DOI:10.1371/journal.pone.0082496 · 3.23 Impact Factor
  • Source
    • "More intriguing in respect to recent interests in mitigation rather than radioprotection is the intimate connection between inflammation and immunity, particularly through the activation and maturation of antigen-presenting cells (APC). The most powerful APC are dendritic cells and, for example, Lord and colleagues investigated the responses of epidermal (Langerhans cells) and interstitial dendritic cells to irradiation, demonstrating that there is a dose-related depletion of cutaneous dendritic cells following irradiation, with both populations sharing similar migratory kinetics following injury (Cummings et al. 2009). Furthermore, the group showed that the immunostimulatory cytokine, IL-12 (BD Biosciences, San Jose, CA, USA), mediated these effects. "
    [Show abstract] [Hide abstract]
    ABSTRACT: PURPOSE: There is increasing concern that, since the Cold War era, there has been little progress regarding the availability of medical countermeasures in the event of either a radiological or nuclear incident. Fortunately, since much is known about the acute consequences that are likely to be experienced by an exposed population, the probability of survival from the immediate hematological crises after total body irradiation (TBI) has improved in recent years. Therefore focus has begun to shift towards later down-stream effects, seen in such organs as the gastrointestinal tract (GI), skin, and lung. However, the mechanisms underlying therapy-related normal tissue late effects, resulting from localised irradiation, have remained somewhat elusive and even less is known about the development of the delayed syndrome seen in the context of whole body exposures, when it is likely that systemic perturbations may alter tissue microenvironments and homeostasis. CONCLUSIONS: The sequence of organ failures observed after near-lethal TBI doses are similar in many ways to that of multiple organ dysfunction syndrome (MODS), leading to multiple organ failure (MOF). In this review, we compare the mechanistic pathways that underlie both MODS and delayed normal tissue effects since these may impact on strategies to identify radiation countermeasures.
    International Journal of Radiation Biology 03/2011; 87(8):851-68. DOI:10.3109/09553002.2011.560996 · 1.69 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The current state of the role of imaging in photodynamic therapy (PDT) has been reported. PDT is a photochemistry-based approach that uses a light activatable chemical, termed a photosensitizer (PS), and light of an appropriate wavelength to impart cytotoxicity via the generation of reactive molecular species. The ability to accurately define tumor margins is a crucial aspect in optimization of surgical interventions and constitutes a major subset of the applications of this fluorescence imaging technique. The traditional implementation of PDT involves the administration of a synthetic PS followed by a period of delay, in which the PS accumulates in the tumor or tissue of interest, before light activation. A major drawback of conventional imaging strategies using one-photon excitation is the limited penetration of visible light into tissue. Progress in imaging technologies, targeting chemistries, and nanotechnology combined with a detailed understanding of PDT-related molecular mechanisms provides optimism for the future of imaging in PDT and may be an important conduit for new applications of PDT and for the development of patient individualized treatments.
    Chemical Reviews 03/2010; 110(5):2795-838. DOI:10.1021/cr900300p · 46.57 Impact Factor
Show more

Preview (2 Sources)

14 Reads
Available from